TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Carcinogenesis Program Direction Changes Near for Extramural research; Workshop Topics Listed April 22, 1977
TCL Archive NCAB Removes Its Restrictions On PDQ Access, Permits NCI Staff To Decide February 7, 1986
